|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma of the salivary gland is a newly recognized entity that morphologically resembles breast secretory carcinoma and has a characteristic t(12;15)(p13;q25) ETV6-NTRK3 translocation.
|
31423558 |
2020 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Histological findings and ETV6-FISH analysis confirmed a parotid SC with high-grade transformation.
|
31679811 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma (SC), which is a common type of minor salivary gland tumor (MSGT), was suspected; however, mammaglobin was negative and ETV6-NTRK3 (EN) fusion was not observed.
|
30634950 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma (SC) of salivary glands is a newly described low-grade malignancy characterized by the presence of ETV6 rearrangement.
|
30942913 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cases included 7 SC with classic ETV6-NTRK3 gene fusion and 3 SC harboring ETV6-RET gene fusion.
|
30130630 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma is a special-type breast carcinoma underpinned by a recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion.
|
31498178 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluorescent <i>in situ</i> hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR) was performed to identify the ETV6-NTRK3 rearrangement of SBC.
|
31119054 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma of the skin is a rare adnexal carcinoma, which is morphologically and immunohistochemically identical to secretory carcinoma of the breast and is associated with the presence of t (12;15) translocation, resulting in the ETV6-NTRK3 gene fusion.
|
31045890 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma (previously known as mammary analogue secretory carcinoma) is characterised by ETV6 rearrangements, most often ETV6-NTRK3 fusion.
|
30801752 |
2019 |
|
Secretory breast carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, numerous molecular/genetic advances in the understanding of salivary gland neoplasms during the last decade have facilitated the development of many useful diagnostic markers, such as PLAG1 and HMGA2 immunohistochemistry for pleomorphic adenoma and ETV6 fluorescence in situ hybridization for secretory carcinoma.
|
30156767 |
2018 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma of salivary gland (MASC) is a tumor with histopathologic and immunophenotypic features mimicking secretory carcinoma of the breast harboring the ETV6 split.
|
29752049 |
2018 |
|
Secretory breast carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The diagnosis was confirmed by demonstrating specific immunohistochemical profile and the presence of ETV6-NTRK3 gene fusion, which is characteristic of secretory carcinoma of other sites.
|
29963997 |
2018 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In order to assess the frequency of variant NTRK3 fusions, and in particular whether the recently identified EML4-NTRK3 fusion is recurrent, 63 archival cases of infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analog secretory carcinoma and secretory breast carcinoma (tumor types that are known to carry recurrent ETV6-NTRK3 fusions) were tested with NTRK3 break-apart FISH, EML4-NTRK3 dual fusion FISH, and targeted RNA sequencing.
|
29099503 |
2018 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rare cases of purported secretory carcinoma of the skin adnexa have been reported, but their relationship to true secretory carcinoma of the breast and salivary glands is unclear, as they generally do not harbor ETV6 rearrangements.
|
27631515 |
2017 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor that shares the same histologic appearance and ETV6 gene (12p13) rearrangement as secretory carcinoma of the breast.
|
27575269 |
2016 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently recognized salivary gland tumor harboring an ETV6-NTRK3 translocation similar to secretory carcinoma of the breast.
|
25456394 |
2015 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We confirmed that ETV6-NTRK3 gene rearrangement and amylase positivity are good diagnostic markers for SC and ACCA, respectively.
|
23944930 |
2013 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor that has morphologic features similar to secretory carcinoma of the breast and that also harbors the same ETV6 translocation.
|
24029710 |
2013 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ETV6-NTRK3 rearrangements have been described in secretory breast carcinoma and congenital fibrosarcoma.
|
21401966 |
2011 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
|
18462362 |
2008 |
|
Secretory breast carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
|
17163160 |
2006 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To demonstrate the reliability of the probes generated with this protocol, four strategies were employed: (i) probes mapping to cyclin D1 (CCND1) were generated and their performance was compared with that of a commercially available probe for the same gene in a series of 10 FFPETS of breast cancer samples of which five harboured CCND1 amplification; (ii) probes targeting cyclin-dependent kinase 4 were used to validate an amplification identified by microarray-based comparative genomic hybridization (aCGH) in a pleomorphic adenoma; (iii) probes targeting fibroblast growth factor receptor 1 and CCND1 were used to validate amplifications mapping to these regions, as defined by aCGH, in an invasive lobular breast carcinoma with FISH and CISH; and (iv) gene-specific probes for ETV6 and NTRK3 were used to demonstrate the presence of t(12;15)(p12;q25) translocation in a case of breast secretory carcinoma with dual colour FISH.
|
16446704 |
2006 |
|
Secretory breast carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, it has been reported that human secretory breast carcinoma expresses the ETV6-NTRK3 gene fusion that was previously cloned in pediatric mesenchymal cancers.
|
15695086 |
2005 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested four histologically confirmed cases of SBC for the presence of the ETV6-NTRK3 gene fusion and then applied the FISH assay to tissue microarrays (TMAs) in order to screen 481 cases of formalin-fixed, paraffin-embedded invasive breast carcinomas of various histologic subtypes.
|
15101049 |
2004 |
|
Secretory breast carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ETV6-NTRK3 (EN) gene fusion occurs in human pediatric spindle cell sarcomas and secretory breast carcinoma, and encodes the oligomerization domain of the ETV6 transcription factor fused to the protein-tyrosine kinase domain of NTRK3.
|
14668342 |
2004 |